English  |  正體中文  |  简体中文  |  Items with full text/Total items : 90453/105672 (86%)
Visitors : 13068072      Online Users : 570
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    ASIA unversity > 護理學院 > 護理學系 > 期刊論文 >  Item 310904400/112907


    Please use this identifier to cite or link to this item: http://asiair.asia.edu.tw/ir/handle/310904400/112907


    Title: Preclinical Evaluation of Exemestane as a Novel Chemotherapy for Gastric Cancer
    Authors: 楊顓丞;張寧;吳登強;鄭維中;鍾瑋敏;張維君;Liu, C-J;Liu, C-J;吳宜珍;賴學洲;馬文隆;Ma, Wen-Lung
    Contributors: 護理學系
    Keywords: aromatase;exemestane;gastric cancer.
    Date: 2019-11
    Issue Date: 2020-09-02 16:00:48 (UTC+8)
    Publisher: 亞洲大學
    Abstract: CYP19A1/aromatase (Ar) is a prognostic biomarker of gastric cancer (GCa). Ar is a critical enzyme for converting androstenedione to oestradiol in the steroidogenesis cascade. For decades, Ar has been targeted with Ar inhibitors (ARIs) in gynaecologic malignancies; however, it is unexplored in GCa. A single-cohort tissue microarray examination was conducted to study the association between Ar expression and disease outcome in Asian patients with GCa. The results revealed that Ar was a prognostic promoter. Bioinformatics analyses conducted on a Caucasian-based cDNA microarray databank showed Ar to be positively associated with GCa prognosis for multiple clinical modalities, including surgery, 5-Fluorouracil (5-FU) for adjuvant chemotherapy, or HER2 positivity. These findings imply that targeting Ar expression exhibits a potential for fulfilling unmet medical needs. Hence, Ar-targeting compounds were tested, and the results showed that exemestane exhibited superior cancer-suppressing efficacy to other ARIs. In addition, exemestane down-regulated Ar expression. Ablating Ar abundance with short hairpin (sh)Ar could also suppress GCa cell growth, and adding 5-FU could facilitate this effect. Notably, adding oestradiol could not prevent exemestane or shAr effects, implicating a nonenzymatic mechanism of Ar in cancer growth. Regarding translational research, treatment with exemestane alone exhibited tumour suppression efficacy in a dose-dependent manner. Combining subminimal doses of 5-FU and exemestane exerted an excellent tumour suppression effect without influencing bodyweight. This study validated the therapeutic potentials of exemestane in GCa. Combination of metronomic 5-FU and exemestane for GCa therapy is recommended.
    Relation: JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
    Appears in Collections:[護理學系] 期刊論文

    Files in This Item:

    File Description SizeFormat
    index.html0KbHTML18View/Open


    All items in ASIAIR are protected by copyright, with all rights reserved.


    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback